ReviewThe oncologist2011
Castleman's disease: from basic mechanisms to molecular therapeutics.
Review in The oncologist, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Idiopathic multicentric Castleman's disease: a systematic literature review.The Lancet. Haematology · 2016Pooled it
- Relapse of HIV-associated multicentric Castleman disease temporally associated with acute coronavirus disease 2019: a case report.BMC infectious diseases · 2026Article
- Snapshot Look at Castleman Disease.Journal of cellular and molecular medicine · 2026Review
- Endoscopic-Assisted Excision of Parotid Castleman Disease in Pediatric Patients: A Case Series of Three Patients and a Literature Review.The American journal of case reports · 2026Review
- Clinical diagnosis and treatment analysis of 11 cases of unicentric Castleman disease in the retroperitoneum.Frontiers in oncology · 2026Article
- [Castleman disease with systemic manifestation: a case report].The Pan African medical journal · 2025Article
- Interleukin-6 transcripts up-regulation in lymph nodes from unicentric and multicentric Castleman disease.EJHaem · 2024Article
- Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses.Med (New York, N.Y.) · 2024Review
- Unraveling TAFRO Syndrome: An In-Depth Look at the Pathophysiology, Management, and Future Perspectives.Biomedicines · 2024Review
- Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease.PharmacoEconomics - open · 2023Article
- Case Report: Castleman Disease With an Associated Stromal Spindle Cell Proliferation,Frontiers in oncology · 2022Article
- Targets and Strategies for Cancer Immunoprevention.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.Frontiers in immunology · 2022Article
- Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease.European journal of haematology · 2021Article
- Castleman Disease Presenting as a Mediastinal Mass.Cureus · 2021Article
- Castleman's disease: Laparoscopic resection of unicentric disease in the hepatic hilum: A case report.Annals of medicine and surgery (2012) · 2021Article
- TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities.International journal of molecular sciences · 2021Review
- Emerging role of 18F-FDG PET/CT in Castleman disease: a review.Insights into imaging · 2021Review
- Abdominal unicentric Castleman's disease: a case report.The Pan African medical journal · 2021Article
- Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature.BMC nephrology · 2020Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Castleman's disease is a rare lymphoproliferative disorder in which there has been recent progress in elucidating underlying mechanisms with potential therapeutic implications. Unicentric Castleman's disease is an indolent condition that is often treated with local approaches. In contrast, patients with multicentric Castleman's disease (MCD) have a less favorable prognosis and require systemic treatment. Cytotoxic chemotherapy, with its attendant risk for toxicity, has been widely used to treat MCD, with variable efficacy. The discovery of putative etiologic factors and targets in MCD, particularly human herpes virus 8, CD20, and interleukin (IL)-6, has been translated into the use of rituximab and anti-IL-6-based therapy, as well as antiviral agents. In this article, we review the current state of the art of our understanding of Castleman's disease and its treatment and we provide insight into future treatment strategies based on disease biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.